Table 1.
In Vivo Experiments of Sodium Bicarbonate Monotherapy in Anticancer Treatment.
| Tumor Type | Model | Administration of NaHCO3 | Reference |
|---|---|---|---|
| Inhibition of metastases | |||
| Breast cancer | MDA-MB-231 xenograft intrasplenic injection | 200 mM NaHCO3 po ad libitum | 20 |
| Prostate cancer | PC3M xenograft tail vein injection | 200 mM NaHCO3 po ad libitum | 20 |
| Melanoma | B16 allograft tail vein injection | 200 mM NaHCO3 po ad libitum | 20 |
| Inducing tumor growth delay | |||
| Prostate cancer | TRAMP | 200 mM NaHCO3 po ad libitum | 24 |
| Breast cancer | MDA-MB-231 cells mice dorsal window chamber | 200 mM NaHCO3 po ad libitum | 15 |
| Colorectal cancer | HCT116 cells mice dorsal window chamber | 200 mM NaHCO3 po ad libitum | 15 |
| Breast cancer | MDA-MB-231 xenograft | A single dose of 21 mg or 84 mg NaHCO3 po | 27 |
| 1 mL 1M NaHCO3 ip injection | |||
| Enhancement immune system | |||
| Melanoma | Yumm 1.1 allograft (CD8+ T-cell) | 200 mM NaHCO3 po ad libitum | 25 |
| B-cell lymphoma | λ-myc mice (NK cells) | 200 mM NaHCO3 po ad libitum | 26 |
Abbreviations: SCID, severe combined immunodeficiency; TRAMP, transgenic adenocarcinoma of mouse prostate; ip, intraperitoneal; po, per os (orally); NK, natural killer.